These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 19203539)

  • 1. Plasma and cellular pharmacokinetics of doxorubicin after intravenous infusion of Caelyx/Doxil in patients with hematological tumors.
    Richly H; Grubert M; Scheulen ME; Hilger RA
    Int J Clin Pharmacol Ther; 2009 Jan; 47(1):55-7. PubMed ID: 19203539
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics (PK) of a liposomal encapsulated fraction containing doxorubicin and of doxorubicin released from the liposomal capsule after intravenous infusion of Caelyx/Doxil.
    Hilger RA; Richly H; Grubert M; Oberhoff C; Strumberg D; Scheulen ME; Seeber S
    Int J Clin Pharmacol Ther; 2005 Dec; 43(12):588-9. PubMed ID: 16372528
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP).
    Linkesch W; Weger M; Eder I; Auner HW; Pernegg C; Kraule C; Czejka MJ
    Eur J Drug Metab Pharmacokinet; 2001; 26(3):179-84. PubMed ID: 11695718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anthracycline dose intensity: clinical pharmacology and pharmacokinetics of high-dose doxorubicin administered as a 96-hour continuous intravenous infusion.
    Synold TW; Doroshow JH
    J Infus Chemother; 1996; 6(2):69-73. PubMed ID: 8809652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doxorubicin pharmacokinetics following a single-dose infusion to sulphur-crested cockatoos (Cacatua galerita).
    Gilbert CM; Filippich LJ; Charles BG
    Aust Vet J; 2004 Dec; 82(12):769-72. PubMed ID: 15648940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of DOX bioavailability in biological samples of mice by sensitive and precise HPLC assay.
    Zhang C; Wu Y; Dong Y; Xu H; Zhao L
    Pharm Biol; 2016; 54(1):55-61. PubMed ID: 25880143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression.
    Martínková J; Bláha M; Kubeček O; Maláková J; Špaček J; Bezouška J; Krulichová IS; Filip S
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):429-37. PubMed ID: 26678853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of infusion regime on doxorubicin pharmacokinetics in the cat.
    Hahn KA; Frazier DL; Cox SK; Legendre AM
    J Am Anim Hosp Assoc; 1997; 33(5):427-33. PubMed ID: 9278119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicokinetics of the active doxorubicin metabolite, doxorubicinol, in sulphur-crested cockatoos (Cacatua galerita).
    Gilbert CM; Filippich LJ; McGeary RP; Charles BG
    Res Vet Sci; 2007 Aug; 83(1):123-9. PubMed ID: 17197005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and metabolism of pirarubicin in humans: correlation with pharmacodynamics.
    Marchiset-Leca D; Leca FR; Galeani A; Noble A; Catalin J
    Cancer Chemother Pharmacol; 1995; 36(3):239-43. PubMed ID: 7781145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation.
    Alibolandi M; Abnous K; Mohammadi M; Hadizadeh F; Sadeghi F; Taghavi S; Jaafari MR; Ramezani M
    J Control Release; 2017 Oct; 264():228-236. PubMed ID: 28844758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intact Doxil is taken up intracellularly and released doxorubicin sequesters in the lysosome: evaluated by in vitro/in vivo live cell imaging.
    Seynhaeve ALB; Dicheva BM; Hoving S; Koning GA; Ten Hagen TLM
    J Control Release; 2013 Nov; 172(1):330-340. PubMed ID: 24012486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
    Charrois GJ; Allen TM
    Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional pharmacokinetics of doxorubicin following hepatic arterial and portal venous administration: evaluation with hepatic venous isolation and charcoal hemoperfusion.
    Iwasaki T; Ku Y; Kusunoki N; Tominaga M; Fukumoto T; Muramatsu S; Kuroda Y
    Cancer Res; 1998 Aug; 58(15):3339-43. PubMed ID: 9699664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic evaluation of intraperitoneal doxorubicin in rats.
    Nagai K; Nogami S; Egusa H; Konishi H
    Pharmazie; 2014 Feb; 69(2):125-7. PubMed ID: 24640601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic study of aldoxorubicin in patients with solid tumors.
    Mita MM; Natale RB; Wolin EM; Laabs B; Dinh H; Wieland S; Levitt DJ; Mita AC
    Invest New Drugs; 2015 Apr; 33(2):341-8. PubMed ID: 25388939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase-I randomized trial of doxorubicin hydrochloride liposome injection versus Caelyx
    Bhowmik S; Bhowmick S; Maiti K; Chakra A; Shahi P; Rajamannar T
    Leuk Lymphoma; 2018 Jun; 59(6):1478-1481. PubMed ID: 28994344
    [No Abstract]   [Full Text] [Related]  

  • 19. [Chemical stability of pirarubicin in its use for continuous infusion].
    Leca F; Marchiset-Leca D; Nobili-Pieri N; Galeani A; Durieux-Joubert A
    Bull Cancer; 1996 Nov; 83(11):923-8. PubMed ID: 9033602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study.
    Mross K; Niemann B; Massing U; Drevs J; Unger C; Bhamra R; Swenson CE
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):514-24. PubMed ID: 15322827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.